Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
Stock Market Today: Nasdaq 100, S&P 500 Futures Gain As Investors Await December Jobs Report— General Motors, Offerpad, Tilray In Focus